logo

For the Inventor, By the Inventor

Newmarket, Canada

Andrew Darke

This inventor holds 12 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Rhodes Pharmaceuticals L.p., Purdue Pharma L.p., Euro-Celtique S.a.. Active years: 2002-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Darke. Retrieved from https://idiyas.com/inventor/andrew-darke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 41.7


Average Co-Inventor Count = 2.2

ph-index = 8

Forward Citations = 344(Granted Patents)


Location History:

  • Ontario, CA (2004 - 2007)
  • Newmarket, CA (2002 - 2019)

Company Filing History:

goldMedal5 out of 10 
 
Rhodes Pharmaceuticals L.p.
 patents
silverMedal4 out of 547 
 
Purdue Pharma L.p.
 patents
bronzeMedal3 out of 270 
 
Euro-Celtique S.a.
 patents

Years Active: 2002-2019

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 10463624 - Controlled release formulations (2019-11-05),
2. 10039719 - Methods of treating attention deficit hyperactivity disorder (2018-08-07),
3. 10022330 - Methods of preparing oral controlled release formulations (2018-07-17),
4. 9949931 - Methods of treating attention deficit hyperactivity disorder (2018-04-24),
5. 9801823 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2017-10-31),
6. 9066869 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2015-06-30),
7. 8580310 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2013-11-12),
8. 7438930 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2008-10-21),
9. 7247318 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2007-07-24),
10. 7083808 - Controlled/modified release oral methylphenidate formulations (2006-08-01),
11. 6673367 - Controlled/modified release oral methylphenidate formulations (2004-01-06),
12. 6419960 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2002-07-16),

Title: The Innovative Contributions of Andrew Darke

Introduction

Andrew Darke is a notable inventor based in Newmarket, Canada, recognized for his significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, Darke has focused on developing advanced drug formulations that enhance therapeutic outcomes.

Latest Patents

Among his latest patents, Darke has developed controlled release formulations aimed at providing a rapid initial onset of effect along with a prolonged duration of effect. These oral modified/controlled release drug formulations are designed to ensure that the peak concentration of the drug is lower than that of immediate release formulations, while also allowing for a swift decline in effect at the end of the dosing interval. Additionally, he has worked on methods for treating attention deficit hyperactivity disorder, utilizing similar controlled release techniques to optimize treatment efficacy.

Career Highlights

Throughout his career, Andrew Darke has been associated with prominent companies in the pharmaceutical industry, including Rhodes Pharmaceuticals L.P. and Purdue Pharma L.P. His work has significantly impacted the development of innovative drug delivery systems.

Collaborations

Darke has collaborated with esteemed professionals in the field, including Thinnayam Naganathan Krishnamurthy and Paul D. Goldenheim, further enhancing the scope and impact of his inventions.

Conclusion

Andrew Darke's innovative work in drug formulation and delivery systems has made a lasting impact on the pharmaceutical industry. His contributions continue to pave the way for advancements in treatment methodologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…